117 related articles for article (PubMed ID: 9732602)
1. Tide is turning on inequality of care.
Mossman J
Nurs Stand; 1998 May 27-Jun 2; 12(36):14-5. PubMed ID: 9732602
[No Abstract] [Full Text] [Related]
2. Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Atkins CD
J Natl Cancer Inst; 2000 Sep; 92(17):1446-7. PubMed ID: 10974091
[No Abstract] [Full Text] [Related]
3. [Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment].
Pecorelli S
Recenti Prog Med; 1999 Jun; 90(6):338-41. PubMed ID: 10399475
[No Abstract] [Full Text] [Related]
4. Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer?
Boccardo F; Miglietta L; Bruzzone M; Rubagotti A; Locatelli MC; Ragni N
Ann Oncol; 2001 Jul; 12(7):1023-4. PubMed ID: 11521789
[No Abstract] [Full Text] [Related]
5. Treatment options for ovarian cancer.
Baker VV
Clin Obstet Gynecol; 2001 Sep; 44(3):522-30. PubMed ID: 11685876
[No Abstract] [Full Text] [Related]
6. Paclitaxel as a component of initial chemotherapy of advanced ovarian cancer: is the controversy resolved.
Markman M
J Cancer Res Clin Oncol; 1998 Jan; 124(1):1-3. PubMed ID: 9498827
[No Abstract] [Full Text] [Related]
7. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for ovarian cancer.
Parmar MK; Sandercock J
N Engl J Med; 1996 May; 334(19):1268-9; author reply 1270. PubMed ID: 8606729
[No Abstract] [Full Text] [Related]
9. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
10. Dose-dense paclitaxel for advanced ovarian cancer.
Zeng YC; Wu R; Xu ZG; Chi F
Lancet; 2010 Jan; 375(9711):280-1; author reply 281. PubMed ID: 20109950
[No Abstract] [Full Text] [Related]
11. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel/carboplatin combination produces impressive response in ovarian cancer patients.
Oncology (Williston Park); 2001 Jul; 15(7):920. PubMed ID: 11499692
[No Abstract] [Full Text] [Related]
13. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
du Bois A; Lück HJ; Meier W; Adams HP; Möbus V; Costa S; Bauknecht T; Richter B; Warm M; Schröder W; Olbricht S; Nitz U; Jackisch C; Emons G; Wagner U; Kuhn W; Pfisterer J;
J Natl Cancer Inst; 2003 Sep; 95(17):1320-9. PubMed ID: 12953086
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
18. [Cytostatic treatment of ovarian carcinoma].
Neijt JP
Ned Tijdschr Geneeskd; 1999 Oct; 143(44):2181-5. PubMed ID: 10578409
[TBL] [Abstract][Full Text] [Related]
19. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
20. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
